---
layout: default
title: Ropivacaine
parent: Low Evidence (L5)
nav_order: 884
evidence_level: L5
indication_count: 10
last_modified_at: 2026-10-14
description: "Ropivacaine: predicted new indication Migraine disorder (evidence level L5). Approved use: Not stated in the Singapore licence data compiled for this report"
---

# Ropivacaine
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **10** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Ropivacaine: From Local Anaesthesia to Migraine Disorder

## One-Sentence Summary

Ropivacaine is a long-acting amide local anaesthetic that is currently marketed in Singapore as injectable and infusion products.
The TxGNN model predicts it may be effective for **migraine disorder**,
with **2 clinical trials** and **3 publications** currently supporting this direction. The evidence is small in scale and mostly based on nerve block or injection procedures.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not stated in the Singapore licence data compiled for this report (all 7 licences have blank indication text); ropivacaine is a local anaesthetic |
| Predicted New Indication | Migraine disorder |
| TxGNN Prediction Score | 99.65% |
| Evidence Level | L2 (see note below) |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 7 |
| Recommended Decision | Hold |

*Note on the evidence level:* The data compiled for this report assigns L2, but the supporting studies are a 10-patient Phase 4 trial, a Phase N/A headache study, and small clinical or observational studies. There is no completed Phase 2/3 RCT specific to migraine, so this level should be read as the upper bound.

---

## Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in the data compiled for this report. Based on general pharmacology, ropivacaine blocks voltage-gated sodium channels in nerve fibres, which produces local anaesthesia and analgesia.

Migraine involves trigeminovascular and autonomic pain signalling. Blocking the sphenopalatine ganglion, the stellate ganglion, or pericranial trigger points with a local anaesthetic can interrupt these pathways. This is a plausible, procedure-based mechanism. However, the studies do not isolate ropivacaine's contribution from that of other local anaesthetics, and the benefit may come from the nerve block procedure itself.

---

## Clinical Trial Evidence

| Trial Number | Phase | Status | Enrollment | Key Findings |
|---------|------|------|------|---------|
| [NCT03666663](https://clinicaltrials.gov/study/NCT03666663) | Phase 4 | Completed | 10 | Randomised, double-blind, placebo-controlled sphenopalatine ganglion block with nasal anaesthetics for migraine prevention. Only 10 participants, so it is underpowered. |
| [NCT00680823](https://clinicaltrials.gov/study/NCT00680823) | N/A | Completed | 150 | Paraspinal intramuscular ropivacaine injection for headache in a paediatric emergency department. The population is headache broadly, not strictly migraine, so the evidence is indirect. |

---

## Literature Evidence

| PMID | Year | Type | Journal | Key Findings |
|------|-----|------|------|---------|
| [17244105](https://pubmed.ncbi.nlm.nih.gov/17244105/) | 2007 | Clinical study | Pain Medicine | Ropivacaine trigger point inactivation for prophylaxis in severe migraine, assessed over 12 weeks |
| [35331152](https://pubmed.ncbi.nlm.nih.gov/35331152/) | 2022 | Observational (cohort) | BMC Anesthesiology | Ultrasound-guided stellate ganglion block to relieve migraine pain and improve quality of life |
| [24284858](https://pubmed.ncbi.nlm.nih.gov/24284858/) | 2013 | Technique / case series | Pain Physician | Revised transnasal topical sphenopalatine ganglion block for headache and facial pain |

---

## Singapore Market Information

| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---------|------|------|-----------|
| SIN17164P | Ropivacaine B. Braun Solution for Injection and Infusion 2 mg/ml | Injection, solution | Not stated |
| SIN09262P | Naropin Infusion 0.2% | Injection | Not stated |
| SIN09264P | Naropin Injection 1% | Injection | Not stated |
| SIN15264P | Ropivacaine-AFT Solution for Infusion 0.2% w/v | Infusion, solution | Not stated |
| SIN15263P | Ropivacaine-AFT Solution for Injection 0.2% w/v | Injection, solution | Not stated |

Two further Ropivacaine-AFT injection licences (0.75% and 1%) are also valid, giving 7 registrations in total.

---

## Safety Considerations

- **Contraindications flagged by the knowledge graph (not label text):** The TxGNN knowledge graph links ropivacaine to a range of conditions as possible contraindications, including:
  - respiratory: COPD, asthma, respiratory failure
  - cardiovascular: cardiovascular disease, heart disease, cor pulmonale
  - neuromuscular: myasthenia gravis, neuromuscular junction disease
  - hepatic, renal and biliary: liver disease, kidney disease, biliary tract disease
  - gastrointestinal: intestinal obstruction, paralytic ileus, inflammatory bowel disease
  - other: butyrylcholinesterase deficiency, substance abuse/dependence, benign prostatic hyperplasia, intracranial hypertension

  These come from graph relationships and should be verified against the official package insert.
- **Drug Interactions:** 64 interactions were identified in total. Moderate-level interactions include obeticholic acid, liposomal morphine, deferasirox and fostamatinib. Most other listed interactions are minor or of unknown severity, for example aprepitant, cimetidine, clarithromycin, atropine and epinephrine.
- **Tissue safety signal:** Several in vitro studies in the tendinitis literature report ropivacaine cytotoxicity to tenocytes. This is relevant if repeated peri-tendinous injection were considered, and it is less directly relevant to migraine.

Please refer to the package insert for the full warnings and contraindications.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The migraine evidence consists of one 10-patient trial, one indirect headache study and a few small observational or technique reports. The benefit may reflect the nerve block procedure rather than ropivacaine specifically, and the data compiled for this report show that the safety review is blocked because package insert information is missing. The TxGNN score is high, but it does not replace clinical evidence.

**To proceed, the following is needed:**
- The HSA package insert warnings and contraindications, to complete the safety screening
- Singapore-approved indication text, since all licence records are blank
- Mechanism of action data from DrugBank
- Effect sizes from the primary papers, particularly PMID 17244105 and the sphenopalatine ganglion block trial
- A comparison against other local anaesthetics, to show whether ropivacaine adds anything specific
- A larger, adequately powered randomised trial in migraine, with a defined route (nerve block or trigger point injection) and a safety monitoring plan

---

## Other Predicted Indications (Brief Note)

Among the other top-ranked predictions, **myofascial pain syndrome** (TxGNN 98.99%) has the strongest supporting evidence. It rests on a completed Phase 4 trial of trigger point injection with ropivacaine plus pregabalin (NCT07866443, n=74) and several comparative studies, and was assessed as "Proceed with Guardrails" in the data compiled for this report. The combination design limits attribution to ropivacaine, and it is not clearly superior to other local anaesthetics.

The remaining predictions (migraine with brainstem aura, nephrogenic syndrome of inappropriate antidiuresis, dysthymic disorder, fibromyalgia, tendinitis, idiopathic granulomatous myositis, myositis fibrosa and bronchitis) have little or no direct evidence and are on **Hold**. Several look like graph artefacts.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

